Autoimmunhyperthyreose: wann langfristig medikamentös behandeln?

Bei der Autoimmunhyperthyreose (Morbus Basedow) gibt es klare Indikationen zu einer primären definitiven Therapie (Radiojodtherapie, Thyreoidektomie). In den letzten Jahren haben sich jedoch Patientengruppen herauskristallisiert, bei denen eine thyreostatische Langzeittherapie eine höhere Remissionsrate und langfristig eine Ausheilung der Erkrankung erreichen kann.

• Literatur

• 1 Laurberg P, Krejbjerg A, Andersen SL. Relapse following antithyroid drug therapy for Graves' hyperthyroidism. Curr Opin Endocrinol Diabetes Obes 2014; 21: 415-421
• 2 Laurberg P, Nygaard B, Andersen S. et al. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res 2014; 2014: 165487
• 3 Kwon H, Kim WG, Jang EK. et al. Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease. Endocrinol Metab (Seoul) 2016; 31: 300-310
• 4 Eckstein AK, Plicht M, Lax H. et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006; 91: 3464-3470
• 5 Liu X, Qiang W, Liu X. et al. A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice. Eur J Endocrinol 2015; 172: 321-326
• 6 Saleh A, Cohnen M, Furst G. et al. Prediction of relapse after antithyroid drug therapy of Graves' disease: value of color Doppler sonography. Exp Clin Endocrinol Diabetes 2004; 112: 510-513
• 7 Allahabadia A, Daykin J, Holder RL. et al. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 1038-1042